The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
114
Publications
1847
Citations
53299
i10-index
561
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Efficacy of Larotrectinib in TRK Fusion–Positive C... | 2018 | 3211 |
The clinical KRAS(G12C) inhibitor AMG 510 drives a... | 2019 | 2484 |
KRAS G12C Inhibition with Sotorasib in Advanced So... | 2020 | 1924 |
Larotrectinib in patients with TRK fusion-positive... | 2020 | 1121 |
Phase 1 study of MRX34, a liposomal miR-34a mimic,... | 2020 | 1087 |
Phase I study of MRX34, a liposomal miR-34a mimic,... | 2016 | 990 |
Autophagy as a target for anticancer therapy | 2011 | 857 |
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreat... | 2022 | 620 |
Activity of XL184 (Cabozantinib), an Oral Tyrosine... | 2011 | 581 |
Personalized Medicine in a Phase I Clinical Trials... | 2012 | 577 |
David S. Hong is a researcher with 1847 publications and 53299 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers and other areas. With an h-index of 114, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from David S. Hong and 300M+ other papers.
Citations per publication by year